Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 9, 2009, Pages 1213-1221

  Dutescu, R Michael ^a,c   Li, Qiao Xin ^a,b   Crowston, Jonathan ^a   Masters, Colin L ^a   Baird, Paul N ^a   Culvenor, Janetta G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Alzheimer's mouse model; Amyloid beta peptide; Amyloid precursor protein; Retina

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CARBOXY TERMINAL SEQUENCE; CELL STRUCTURE; CELLULAR DISTRIBUTION; CEREBELLUM; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RETINA GANGLION CELL; RETINOPATHY; SPECIES COMPARISON; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BLOTTING, WESTERN; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM, CORNEAL; LENS, CRYSTALLINE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; RETINAL DISEASES; RETINAL GANGLION CELLS;

EID: 68549111222     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1060-3     Document Type: Article

References (32)

1. Mendez MF, Mendez MA, Martin R, Smyth KA, Whitehouse PJ (1990) Complex visual disturbances in Alzheimer's disease. Neurology 40:439-443
2. Tippett WJ, Krajewski A, Sergio LE (2007) Visuomotor integration is compromised in Alzheimer's disease patients reaching for remembered targets. Eur Neurol 58:1-114. doi: 10.1159/000102160
3. Gary (1989) Abnormal pattern electroretinograms in patients with sede dementia of the alzheimer type. Ann Neurol 26:226-231
4. Iseri PK, Altinas O, Tokay T, Yuksel N (2006) Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 26:18-24. doi: 10.1097/01.wno.0000204645.56873.26
5. Ojima T, Tanabe T, Hangai M, Yu S, Morishita S, Yoshimura N (2007) Measurement of retinal nerve fiber layer thickness and macular volume for glaucoma detection using optical coherence tomography. Jpn J Ophthalmol 51:197-203. doi: 10.1007/s10384-006-0433-y
6. Bayer AU, Keller ON, Ferrari F, Maag KP (2002) Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol 133:135-137. doi: 10.1016/S0002-9394(01)01196-5
7. Syed AB, Armstrong RA, Smith CU (2005) A quantitative analysis of optic nerve axons in elderly control subjects and patients with Alzheimer's disease. Folia Neuropathol 43:1-69
8. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249. doi: 10.1073/ pnas.82.12.4245
9. Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH (1991) Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem J 275(Pt 1):99-104
10. Evin G, Weidemann A (2002) Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides. Peptides 23:1285-1297. doi: 10.1016/ S0196-9781(02)00063-3
11. Janciauskiene S, Krakau T (2001) Alzheimer's peptide: A possible link between glaucoma, exfoliation syndrome and Alzheimer's disease. Acta Ophthalmol Scand 79:328-329. doi: 10.1034/j.1600-0420.2001.790327.x
12. Janciauskiene S, Krakau T (2003) Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome. Doc Ophthalmol 106:215-223. doi: 10.1023/A:1022949121078
13. Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, Hisatomi T, Mochizuki M, Morita I (2005) The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 115:2793-2800. doi: 10.1172/JCI24635
14. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT Jr, Bush AI (2003) Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 361:1258-1265. doi: 10.1016/S0140-6736(03)12981-9
15. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito AM, Cheetham ME, Moss SE, Fitzke FW, Cordeiro MF (2007) Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 104:13444-13449. doi: 10.1073/pnas.0703707104
16. Goldblum D, Kipfer-Kauer A, Sarra GM, Wolf S, Frueh BE (2007) Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest Ophthalmol Vis Sci 48:5085-5090. doi: 10.1167/iovs.06-1249
17. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1:1291-1296. doi: 10.1038/nm1295-1291
18. Prihar G, Verkkoniem A, Perez-Tur J, Crook R, Lincoln S, Houlden H, Somer M, Paetau A, Kalimo H, Grover A, Myllykangas L, Hutton M, Hardy J, Haltia M (1999) Alzheimer disease PS-1 exon 9 deletion defined. Nat Med 5:1090. doi: 10.1038/13383
19. Ning A, Cui JZ, To E, Hsiao Ashe K, Matsubara JA (2008) Amyloid beta deposits lead to retinal degeneration in a mouse model of alzheimer disease. Invest Ophthalmol Vis Sci
20. Shimazawa M, Inokuchi Y, Okuno T, Nakajima Y, Sakaguchi G, Kato A, Oku H, Sugiyama T, Kudo T, Ikeda T, Takeda M, Hara H (2008) Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling. J Neurochem 107:279-290. doi: 10.1111/j.1471-4159.2008.05606.x
21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102. doi: 10.1126/ science.274.5284.99
22. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol Eng 17:157-165. doi: 10.1016/ S1389-0344(01)00067-3
23. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908-22914. doi: 10.1074/ jbc.271.37.22908
24. Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P (1990) Processing of Alzheimer beta/A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 87:6003-6006. doi: 10.1073/pnas.87.15.6003
25. Culvenor JG, Henry A, Hartmann T, Evin G, Galatis D, Friedhuber A, Jayasena UL, Underwood JR, Beyreuther K, Masters CL, Cappai R (1998) Subcellular localization of the Alzheimer's disease amyloid precursor protein and derived polypeptides expressed in a recombinant yeast system. Amyloid 5:79-89
26. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, Li QX, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL (2007) In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27:10365-10371. doi: 10.1523/JNEUROSCI.0630-07.2007
27. Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jakala P, Hartmann T, Beyreuther K, Masters CL, Li QX (1999) Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 155:1173-1181
28. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741. doi: 10.1126/science.286.5440.735
29. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51:783-786. doi: 10.1002/ana.10208
30. Lehman EJ, Kulnane LS, Lamb BT (2003) Alterations in beta-amyloid production and deposition in brain regions of two transgenic models. Neurobiol Aging 24:645-653. doi: 10.1016/S0197-4580(02)00153-7
31. Evin G, Zhu A, Holsinger RM, Masters CL, Li QX (2003) Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res 74:386-392. doi: 10.1002/jnr.10745
32. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J (2007) Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 420:97-99. doi: 10.1016/ j.neulet.2007.02.090